Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosentyx in Necrobiosis Lipoidica Diabeticorum
NCT03791060Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of secukinumab in necrobiosis lipoidica diabeticorum (NLD), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Investigator Global Assessment at 24 weeks. Started Apr 2019; status: terminated.
02
Drugs
secukinumab
03
Conditions
necrobiosis lipoidica diabeticorum (NLD)
Beyond the preview
Go deeper on NCT03791060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791060.